Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

576 VINBLASTINE
Neurotoxicity
(1992): Hansen SW, Dan Med Bull 39(5), 391 (with bleomycin &
vinblastine)
Phlebitis
(1989): Kerker BJ+, Semin Dermatol 8, 173
Rhabdomyolysis
(1995): Anderlini P+, Cancer 76(4), 678
VINCRISTINE
Trade name: Vincasar (Gensia)
Indications: Leukemias, lymphomas, neuroblastoma, Wilm’s
tumor
Category: Antimitotic; Vinca alkaloid
Half-life: 24 hours
Clinically important, potentially hazardous interactions
with: aldesleukin, aprepitant, bromelain, fluconazole, influenza
vaccines, itraconazole, ketoconazole, miconazole
Reactions
Skin
Acral erythema
(1995): Komamura H+, JDermatol22(2), 116 (with
cyclophosphamide, doxorubicin and GCSF)
Actinic keratoses
(1987): Johnson TM+, JAmDermatol17(2 Pt 1), 192
Allergic reactions
(2005): Nakashima H+, Br J Dermatol 153(1), 225
Angioedema
(1984): Gassel WD+, Oncology 41, 403
Dermatitis herpetiformis
(1986): Gottlieb D+, Med J Aust 145, 241 (flare)
Edema
Erythroderma
(1989): Matsumoto N+, Gan To Kagaku Ryoho (Japanese)
16, 2297
(1984): Gassel WD+, Oncology 41, 403
Exanthems
(1984): Gassel WD+, Oncology 41, 403
Hand–foot syndrome
(2003): Leighl NB+, Clin Lung Cancer 5(2), 107 (with
doxorubicin and cyclophosphamide)
(2002): Hussein MA+, Cancer 95(10), 2160 (with
dexamethasone)
Palmar–plantar erythema
(1990): Pagliuca A+, Postgrad Med J 66, 242
Pigmentation
(2000): Marcoux D+, JAmAcadDermatol43, 540 (with
dactinomycin)
Pruritus
Rash (sic) (1–10%)
Raynaud’s phenomenon
(2004): Gottschling S+, J Pediatr Hematol Oncol 26(11), 768
(1998): Reiser M+, Eur J Clin Microbiol Infect Dis 17, 58
Urticaria
Mucosal
Oral lesions (1–10%)
(1989): KerkerBJ+, Semin Dermatol 8, 173 (1–5%)
Oral ulceration (1–10%)
Stomatitis (10%)
(1983): BronnerAK+, JAmAcadDermatol9, 645
Injection-site extravasation
(2000): Kassner E, JPediatrOnconNurs17, 135
Injection-site necrosis (>10%)
Myalgia/Myositis/Myopathy/Myotoxicity (1–10%)
Neurotoxicity
(2004): Schiavetti A+, Pediatr Blood Cancer 43(5), 606
Phlebitis (1–10%)
VINORELBINE
Trade name: Navelbine (Kyowa)
Indications: Non-small cell lung cancer
Category: Antimitotic; Vinca alkaloid
Half-life: 28–44 hours
Clinically important, potentially hazardous interactions
with: aldesleukin
Reactions
Skin
Angioedema
Erythema
Hand–foot syndrome
(2004): Martin M+, Clin Breast Cancer 5(5), 353 (6%) (with
doxorubicin)